RT Journal Article
SR Electronic
T1 Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.02.20222166
DO 10.1101/2020.11.02.20222166
A1 Zhen-Yi Andy Ou
A1 Lauren M. Byrne
A1 Filipe B. Rodrigues
A1 Rosanna Tortelli
A1 Eileanoir B. Johnson
A1 Martha S. Foiani
A1 Marzena Arridge
A1 Enrico De Vita
A1 Rachael I. Scahill
A1 Amanda Heslegrave
A1 Henrik Zetterberg
A1 Edward J. Wild
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.02.20222166.abstract
AB Brain-derived neurotrophic factor (BDNF) is implicated in the survival of striatal neurons. BDNF function is reduced in Huntington’s disease (HD), possibly because mutant huntingtin impairs its cortico-striatal transport, contributing to striatal neurodegeneration. The BDNF trophic pathway is a therapeutic target, and blood BDNF has been suggested as a potential biomarker for HD, but BDNF has not been quantified in cerebrospinal fluid (CSF) in HD.BDNF in CSF and plasma in the HD-CSF cohort (20 pre-manifest and 40 manifest HD mutation carriers and 20 age and gender-matched controls) were quantified using conventional ELISAs and an ultra-sensitive immunoassay.BDNF concentration was below the limit of detection of the conventional ELISAs, raising doubt about previous CSF reports in neurodegeneration. Using the ultra-sensitive method, BDNF concentration was quantifiable in all samples but did not differ between controls and HD mutation carriers in CSF or plasma, was not associated with clinical scores or MRI brain volumetric measures, and had poor ability to discriminate controls from HD mutation carriers, and premanifest from manifest HD.BDNF in CSF and plasma is unlikely to be a biomarker of HD progression, and urge caution in interpreting studies where conventional ELISA was used to quantify CSF BDNF.Competing Interest StatementZAO, LMB, FBR, MF, RT, EBJ, RIS, AH, HZ, EJW are University College London employees. MA is a University College London Hospitals NHS Foundation Trust employee. EDV is a King's College London employee. LMR has provided consultancy services to GLG, F. Hoffmann-La Roche Ltd, Genentech and Annexon. FBR has provided consultancy services to GLG and F. Hoffmann-La Roche Ltd. RIS has undertaken consultancy services for Ixitech Ltd. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). EJW reports grants from Medical Research Council, CHDI Foundation, and F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Hoffman La Roche Ltd, Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda and Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals.Clinical Protocols https://doi.org/10.5522/04/11828448.v1 Funding StatementThis work was supported by the Medical Research Council UK, the CHDI foundation, the Huntington's Disease Society of America, the Hereditary Disease Foundation, the Wellcome Trust (Wellcome Collaborative Award In Science 200181/Z/15/Z and Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z]), the Department of Health's NIHR Biomedical Research Centres funding scheme, F. Hoffmann-La Roche Ltd, Horizon 2020 Framework Programme, the Swedish Research Council, the European Research Council, and Swedish State Support for Clinical Research, and the Innovative Medicines Initiative Joint Undertaking under EMIF grant. HZ is a Wallenberg Scholar.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:It was conducted according with the Declaration of Helsinki and was approved by the London-Camberwell St Giles Research Ethics Committee. All participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, EJW, upon reasonable request.